In arteries with endothelium, thrombin (0.01 to 1 U/mL) induced endothelium-dependent relaxations, which were reduced by the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 10m ol/L) and/or indomethacin (10-' mol/L). Human platelets (75 000/gL) evoked only marginal contractions in arteries with endothelium (3+3% of the contraction to KCl 100 mmol/L; NS), which were markedly enhanced by endothelial removal (22±4%; P<.05). Thrombin (1 U/mL) did not affect the response to platelets in arteries with (6+±5%; NS) but induced thrombotic coronary artery occlusion and in particular in vascular reocclusion after coronary thrombolysis and angioplasty.'0-'2 Antithrombin therapy appears to prevent vascular reocclusion after thrombolysis in the animal model.11 '12 In addition to platelets, thrombin specifically activates endothelial cells of human arteries.13"4 Endothelial cells manifest antithrombotic activity by releasing vasoactive substances with antiplatelet activities such as the endothelium-derived nitric oxide15-'8 and prostacyclin. 19 Platelet-derived substances (ie, adenine nucleotides, serotonin) and thrombin, on the other hand, cause endothelium-dependent relaxation, at least in certain blood vessels.20-25 Hence, platelet-derived substances such as serotonin, ADP, and ATP as well as thrombin can activate platelets and stimulate the release of nitric oxide and prostacyclin from the endothelium. Thus, depending on the functional status of the endothelium, these substances should differentially regulate platelet-vessel wall interaction. Since endothelial dysfunction, and in particular a decreased release of nitric oxide and prostacyclin, occurs in coronary artery disease,25-27 these mechanisms may have important implications in unstable angina and myocardial infarction.
This study was designed to investigate the potential role of thrombin as a regulator of platelet-vessel wall interaction as well as the effects of antiplatelet drugs in human arteries.
Methods Preparation of Blood Vessels
Internal mammary arteries were obtained intraoperatively as previously described.14 Coronary arteries were obtained from patients with cardiomyopathy who underwent heart transplantation. After removal, vessels were placed into modified Krebs 
Experimental Setup
Vascular rings were suspended in organ chambers, and changes in isometric tension were recorded with force transducers (Statham Universal UC2). Before the experiment, the rings were stretched and repeatedly exposed to norepinephrine (3x 10-mol/L) or prostaglandin F2. (10-6 mol/L) until a passive tension of 4 g was reached28; then they were allowed to equilibrate for 45 minutes.
Endothelium Removal
The endothelium was removed from some rings by gentle rubbing of the intraluminal surface with a cotton swab. The presence or absence of the endothelium was confirmed by the presence or absence of a relaxation to acetylcholine (10-6 mol/L, internal mammary artery) or bradykinin (10-6 mol/L, coronary artery).
Preparation of Platelets
Platelets were prepared as previously described. 
Protocols and Statistics
To study the effects of thrombin on platelet-vessel wall interaction, arteries with and without endothelium were exposed to platelets (75 000/4L). Previous studies have demonstrated that platelets readily aggregate in organ chambers22'23 and release significant amounts of adenine nucleotides, serotonin, and thromboxane.22-24 After the contraction to platelets had stabilized, thrombin (1 U/mL) was added. To delineate the mediator released from thrombin-stimulated platelets, arteries without endothelium were exposed (in the presence of 1 U/mL thrombin) to platelets (1000 to 75 000/ giL). After 
Results

Vascular Effects of Aggregating Platelets
In the internal mammary artery with endothelium pretreated with indomethacin (10-`mol/L), platelets (75 000/,uL) evoked only a marginal contraction (6±2% of the response to 100 mmol/L KCl), which was markedly enhanced by the specific inhibitor of nitric oxide formation L-NMMA (10-3 mol/L; 20±6%, P<.05; n=4; Fig 1) . Removal of the endothelium unmasked a contraction to platelets comparable to that of L-NMMA (from 3±3% to 22±4%; P<.05; n=4).
Vascular Effects of Thrombin
In internal mammary and coronary arteries, thrombin (0.01 to 1 U/mL) induced a marked concentrationdependent and endothelium-dependent relaxation (maximal relaxation, 53±7% and 75±9%, respectively; n=4; Fig 2) .
In mammary arteries, concentration-response curves to thrombin (0.01 to 1 U/mL) were somewhat reduced by the addition of L-NMMA (10`mol/L to inhibit nitric oxide production20'3435; NS; n=6) and particularly with L-NAME (10-4 mol/L; P<.01; n=4) or indomethacin (10`mol/L; to inhibit vascular prostacyclin pro- In mammary arteries, the relaxations to a single concentration of thrombin (1 U/mL; 53±7%) were not affected by the cyclooxygenase inhibitor indomethacin (10-5 mol/L; 47±7%) nor by the inhibitor of nitric oxide production L-NMMA (10-3 mol/L; 51±13%) alone but were abolished with combined treatment with the two inhibitors (P<.001 versus control; Table) . Thrombin and Platelet-Vessel Wall Interaction Under control conditions, platelets (75 000/gL) evoked no significant change in tension (3 ± 3%) in quiescent arteries with endothelium but marked contractions after removal of the endothelium (Fig 4; 22±4%; P<.05; n=4). In arteries with endothelium, the addition of thrombin (1 U/mL) did not significantly affect the response to platelets (change in tension, 6±5%; NS; n=4) but caused a prominent further platelet-induced contraction in vessels without endothelium (Fig 4; 53±6% ; P<.01 versus control without endothelium; n=4).
Effects of Thromboxane Inhibitors
Increasing concentrations of platelets (1000 to 75 000/ ptL) activated by thrombin (1 U/mL) were added to internal mammary arteries without endothelium. Under these conditions, the activated platelets induced marked and concentration-dependent contractions (Fig 5, left) . These contractions were markedly antagonized by the combined thromboxane A2 synthetase inhibitor/receptor antagonist ridogrel (Fig 5, left In an internal mammary artery (A) and a coronary artery (B) contracted with either norepinephrine (NE) or prostaglandin F2,' (PGF2a), thrombin concentration-dependently evoked potent endothelium-dependent relaxations (C). (Fig 5, left; 10-7 mol/L; 44±+9%), although this did not reach statistical significance.
SQ-30741
In parallel experiments, the effects of ridogrel mol/L) and SQ-30741 (10`' mol/L) on the contractions induced by the thromboxane analogue U-46619 were tested (Fig 5, right) . Both drugs at the concentrations used to inhibit platelet-induced contractions exhibited equal potency in inhibiting contractions evoked by U-46619 (10-fold shift of the control EC50; P<.0001) without reducing the maximal response (SQ-30741, 154±+8% and ridogrel, 133±+-7% versus control, 150±+6%; NS).
Discussion
The present study demonstrates the protective role of the endothelium as an inhibitor of platelet-vessel wall interactions, in particular during activation with thrombin. In arteries with functionally intact endothelium, thrombin releases enough prostaglandins and nitric oxide from the human mammary and coronary artery 1 cells linked to the release of nitric oxide.22 '26 In precontracted arteries, aggregating platelets cause endothelium-dependent relaxations, despite the concomitant release of potent vasoconstrictors such as serotonin and thromboxane A2 from platelets. 22 In quiescent arteries used in this study, endothelial removal as well as the inhibitor of nitric oxide production L-NMMA34,35 unmasked platelet-induced contractions. This suggests that in arteries with endothelium, platelet-induced contractions are prevented by the release of nitric oxide in response to platelet-derived products. The fact that even a high concentration of aggregating platelets was unable to induce significant vasoconstriction in arteries with endothelium demonstrates the potency of the endothelial L-arginine/nitric oxide pathway as an inhibitor of platelet-vessel wall interaction.
At sites at which platelets are activated in vivo, the coagulation cascade is activated as well, which in turn leads to the formation of thrombin. Thrombin can stimulate both the endothelium (but not vascular smooth muscle of human arteries13.14) and the platelets themselves. Indeed, in the human internal mammary and coronary arteries, thrombin caused pronounced endothelium-dependent relaxations. When concentration-response curves to thrombin were constructed, L-NMMA tended to inhibit that response,36 whereas L-NAME or indomethacin was more effective. Complete inhibition of the effect was achieved with the combination of the two drugs. With a single high concentration of thrombin, neither indomethacin nor L-NMMA was effective alone, and only the combination was able to fully prevent the response. These slightly different results under both experimental conditions could be due to a more important contribution of prostacyclin over the entire concentration range of thrombin studied, whereas nitric oxide may be more important at higher concentrations. Alternatively, since the response to thrombin is associated with tachyphylaxis,20 tolerance of the response may affect mechanisms linked to nitric oxide production more than those to prostacyclin. Hence, at a single high concentration of thrombin, activation of either pathway may be efficient enough to retain a response, whereas with repeated application of increasing concentrations of thrombin, the production of nitric oxide may be downregulated. In line with this interpretation, the maximal relaxation to thrombin was slightly more pronounced with a single concentration of the enzyme compared with a cumulative concentration-response curve. An interaction between nitric oxide and prostacyclin also has been demonstrated in human platelets,18 in intact porcine coronary37 and mammary arteries,28 and in endothelial cells in culture38; under the latter conditions, nitric oxide inhibits the production of prostacyclin; hence, most likely after blockade of nitric oxide, more prostacyclin is formed to substitute for the effects of the endogenous nitrovasodilator.
In arteries with endothelium, thrombin did not stimulate platelet-induced contractions, although platelets were further stimulated to To This study suggests that thrombin is an important amplifier of platelet-vessel wall interactions in arteries without normal endothelium. Since thromboxane A2 plays a major role, a combined inhibitor of thromboxane formation and action may represent an important therapeutic tool. It remains to be shown whether such a drug provides a greater benefit than aspirin.46
